Genomics: Pharmaceutical Investment, Integration and Partnerships assesses the value of genomics to pharmaceutical companies and the most cost-effective way in which this value can be realized in improved R&D pipelines. Based on case studies of leading and emerging genomics companies and their pharmaceutical partners, this report identifies best practice in genomics alliances. The report further forecasts how the increasing maturity of the genomics industry will change the balance of power in favor of genomics providers, highlighting the need for an innovative approach by pharmaceutical companies to gain access to this vital technology.
